MRI/S biomarkers to improve cancer drug development
A biomarker is now defined as“a characteristic that is objectively measured and evaluated aS all indicator of normal biological processes,pathogenic processes,or pharmacologic responses to a therapeutic intervention”.In contradistinction,a clinical endpoint describes how a patient“feels,functions or survives”.In ontology research and practice,almost any objective imaging measurement Can be described as an imaging biomarker(IB),even traditional measurements of size,or tumour-node.metastasis(TNM)status. IBs may be diagnostic/prognostic(IB reveals turnout phenotype);predictive(IB dictates which treatment for patient),monitoring(IB determines when to change treatment),or response(IB implies treatmentbenefit orharm).
John Waterton
Biomedical Imaging Institute,Manchester Academic Health Sciences Centre,University of Manchester Oxford Road,MANCHESTER M13 9PT UK
国内会议
第二十届中国国际医用仪器设备展览会暨技术交流会、中放磁共振年会暨国际磁共振研讨会
北京
英文
66-67
2011-08-18(万方平台首次上网日期,不代表论文的发表时间)